Sage rethinks SAGE-217 program after phase 3 failure

Sage rethinks SAGE-217 program after phase 3 failure

Source: 
Fierce Biotech
snippet: 

Sage Therapeutics has suspended enrollment in two clinical trials of its depression drug in response to the failure of a phase 3 study. The action is intended to give Sage time to talk to the FDA and weigh potential amendments to the two paused phase 3 trials.